Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents

Journal of Cardiovascular Development and Disease

Nikolaos Panagiotou¹  Ioannis Paraskevaidis¹  Alexandros Sianis¹  Alexandros Briasoulis¹  Angeliki Chasouraki¹  Argyrios Ntalianis¹  Christos Kourek¹ 

[1] Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece;

关键词: cardiotoxicity;    cardiac dysfunction;    non-anthracycline agents;    chemotherapy;    immunotherapy;    cardioprotection;   

DOI  :  10.3390/jcdd9030066

来源: DOAJ

【 摘 要 】

Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.

【 授权许可】

Unknown